{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T09:19:42Z","timestamp":1774084782789,"version":"3.50.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>We aimed to develop population pharmacokinetic (PK) models of ampicillin and sulbactam using pooled data analysis and to optimize dosing regimens of ampicillin-sulbactam (combination ratio of 2:1) in pediatric patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Population PK models of ampicillin and sulbactam were separately developed by simultaneously fitting plasma and urine data from pediatric patients in 14 published studies. Based on these models, we estimated the probability of attaining a pharmacodynamic (PD) target [50% of time that free drug concentrations above the minimum inhibitory concentration, 50% <jats:italic toggle=\"yes\">f<\/jats:italic>T &gt; minimum inhibitory concentration (MIC)] against MIC<jats:sub>90<\/jats:sub> [MIC that blocked the growth of 90% of the strains] of common bacteria in community-acquired pneumonia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The analysis included 54 pediatric patients (0.083\u201316.42 years of age, 4.0\u201377.0\u2009kg of body weight). A total of 284 plasma concentrations and 90 urinary excretions from 0 to 6 hours after administration were used for population PK modeling. The data were adequately described by 2-compartment models for ampicillin and sulbactam. Age was not a statistically significant covariate in the PK of either drug. The PK\/PD breakpoint MICs for 45\u2009mg\/kg 3 times daily and 75\u2009mg\/kg 4 times daily (q.i.d.) were 0.25 and 1 \u03bcg\/mL, respectively. For empiric therapy of community-acquired pneumonia, because MIC<jats:sub>90<\/jats:sub> values for the main target pathogens is high (MIC<jats:sub>90<\/jats:sub> = 2 \u03bcg\/mL for <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic> and MIC<jats:sub>90<\/jats:sub> = 4 \u03bcg\/mL for <jats:italic toggle=\"yes\">Haemophilus influenzae<\/jats:italic>), 75\u2009mg\/kg q.i.d. (Food and Drug Administration\u2013approved maximum dosage in United States) might be better than 45\u2009mg\/kg 3 times daily (within approved dosage in Japan) to cover many pathogens.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>From the results of this PK\/PD approach, 75\u2009mg\/kg q.i.d. (Food and Drug Administration\u2013approved maximum dosage) should be recommended in the empiric therapy of community-acquired pneumonia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000003496","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T16:23:47Z","timestamp":1645633427000},"page":"411-416","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data"],"prefix":"10.1097","volume":"41","author":[{"given":"Tetsushu","family":"Onita","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan"},{"name":"Department of Pharmacy, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuro","family":"Ikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Tamaki","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Yano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohji","family":"Naora","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Morikawa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"issue":"suppl 5","key":"R3-20250615","doi-asserted-by":"crossref","first-page":"S634","DOI":"10.1093\/clinids\/8.Supplement_5.S634","article-title":"A randomized comparative study of sulbactam plus ampicillin vs. metronidazole plus cefotaxime in the management of acute appendicitis in children.","volume":"8","author":"Foster","year":"1986","journal-title":"Rev Infect Dis"},{"issue":"suppl 5","key":"R4-20250615","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1093\/clinids\/8.Supplement_5.S512","article-title":"Single-dose pharmacokinetics of intravenous sulbactam in pediatric patients.","volume":"8","author":"Schaad","year":"1986","journal-title":"Rev Infect Dis"},{"key":"R5-20250615","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1128\/AAC.43.5.1225","article-title":"Pharmacokinetics of ampicillin and sulbactam in pediatric patients.","volume":"43","author":"Nahata","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 5","key":"R6-20250615","doi-asserted-by":"crossref","first-page":"S518","DOI":"10.1093\/clinids\/8.Supplement_5.S518","article-title":"Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn.","volume":"8","author":"Sutton","year":"1986","journal-title":"Rev Infect Dis"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"issue":"suppl 3","key":"R8-20250615","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1086\/321854","article-title":"Does the dose matter?","volume":"33","author":"Craig","year":"2001","journal-title":"Clin Infect Dis"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/INF.0b013e31829b5880","article-title":"Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children.","volume":"32","author":"Yoshizawa","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.2042-7158.2010.01179.x","article-title":"Indications for a ceftriaxone dosing regimen in Japanese paediatric patients using population pharmacokinetic\/pharmacodynamic analysis and simulation.","volume":"63","author":"Iida","year":"2011","journal-title":"J Pharm Pharmacol"},{"key":"R11-20250615","first-page":"579","article-title":"[Pharmacokinetic and bacteriological studies on sulbactam\/ampicillin in the field of pediatrics].","volume":"42","author":"Sato","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R12-20250615","first-page":"612","article-title":"[Clinical evaluation of sulbactam\/ampicillin in the pediatric infections].","volume":"42","author":"Meguro","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R13-20250615","first-page":"623","article-title":"[Clinical and pharmacokinetic studies on intravenous administration of sulbactam\/ampicillin in pediatrics].","volume":"42","author":"Sato","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R14-20250615","first-page":"639","article-title":"[Pharmacokinetic, bacteriological and clinical studies on sulbactam\/ampicillin in pediatric field].","volume":"42","author":"Nakao","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R15-20250615","first-page":"651","article-title":"[Pharmacokinetic and clinical studies on sulbactam\/ampicillin in the pediatric field].","volume":"42","author":"Ito","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R16-20250615","first-page":"662","article-title":"[Studies on sulbactam\/ampicillin in the field of pediatrics].","volume":"42","author":"Nakamura","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R17-20250615","first-page":"675","article-title":"[Clinical evaluation of sulbactam\/ampicillin in children].","volume":"42","author":"Ito","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R18-20250615","first-page":"687","article-title":"[Laboratory and clinical studies of sulbactam\/ampicillin in pediatric field].","volume":"42","author":"Nishimura","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R19-20250615","first-page":"701","article-title":"[Pharmacokinetic and clinical studies on sulbactam\/ampicillin in children].","volume":"42","author":"Hattori","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R20-20250615","first-page":"719","article-title":"[Bacteriological, pharmacokinetic and clinical studies of sulbactam\/ampicillin in the pediatric field].","volume":"42","author":"Haruta","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R21-20250615","first-page":"733","article-title":"[Clinical experience with sulbactam\/ampicillin in the pediatric field].","volume":"42","author":"Sekiguchi","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R22-20250615","first-page":"743","article-title":"[Pharmacokinetic, bacteriological and clinical evaluation of sulbactam\/ampicillin in pediatrics].","volume":"42","author":"Hayashi","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R23-20250615","first-page":"754","article-title":"[Pharmacokinetic and clinical studies on sulbactam\/ampicillin in the pediatric field].","volume":"42","author":"Yanagishima","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R24-20250615","first-page":"773","article-title":"[Pharmacokinetic, bacteriological and clinical studies of sulbactam\/ampicillin in pediatric patients].","volume":"42","author":"Motohiro","year":"1989","journal-title":"Jpn J Antibiot"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","article-title":"Perl-speaks-NONMEM (PsN)\u2013a Perl module for NONMEM related programming.","volume":"75","author":"Lindbom","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"R26-20250615","first-page":"71","article-title":"Surveillance of in vitro susceptibilities to levofloxacin and various antibacterial agents for 11,705 clinical isolates obtained from 65 centers in 2016.","volume":"298","author":"Tateda","year":"2018","journal-title":"Jpn J Antibiot"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1198-743x.2001.00295.x","article-title":"Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.","volume":"7","author":"Jacobs","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 1","key":"R29-20250615","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1086\/344653","article-title":"Prevention of resistance: a goal for dose selection for antimicrobial agents.","volume":"36","author":"Drusano","year":"2003","journal-title":"Clin Infect Dis"},{"issue":"suppl. 8","key":"R30-20250615","first-page":"34","article-title":"Antibacterial activity of sulbactam ampicillin.","volume":"36","author":"Kawasaki","year":"1988","journal-title":"Chemotherapy"},{"issue":"7 suppl","key":"R31-20250615","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jiac.2015.12.019","article-title":"JAID\/JSC guidelines for the treatment of respiratory infectious diseases: The Japanese Association for Infectious Diseases\/Japanese Society of Chemotherapy - The JAID\/JSC Guide to Clinical Management of Infectious Disease\/Guideline-preparing Committee Respiratory Infectious Disease WG.","volume":"22","author":"Mikasa","year":"2016","journal-title":"J Infect Chemother"},{"key":"R33-20250615","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bcp.12232","article-title":"Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.","volume":"77","author":"Soto","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R34-20250615","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/jcph.1800","article-title":"Prostatic pharmacokinetic\/pharmacodynamic evaluation of Ampicillin-Sulbactam for bacterial prostatitis and preoperative prophylaxis.","volume":"61","author":"Onita","year":"2021","journal-title":"J Clin Pharmacol"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003496","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:04:01Z","timestamp":1750003441000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000003496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000003496","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,8]]}}}